Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 331 to 345 of 2548 results for methods

  1. Enlicitide decanoate for treating hyperlipidaemia in people at risk of an atherosclerotic cardiovascular disease event [ID6656]

    Awaiting development Reference number: GID-TA11871 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Iptacopan for treating primary IgA nephropathy [ID6640]

    Awaiting development Reference number: GID-TA11844 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Zanubrutinib with rituximab for untreated mantle cell lymphoma when a stem cell transplant is unsuitable [ID6641]

    Awaiting development Reference number: GID-TA11843 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer [ID6444]

    Awaiting development Reference number: GID-TA11560 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. CAEL-101 with standard care for untreated amyloid light chain amyloidosis [ID6210]

    Awaiting development Reference number: GID-TA11182 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Ondansetron for treating alcohol-use disorder [ID6341]

    Awaiting development Reference number: GID-TA11375 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Ruxolitinib for treating moderate atopic dermatitis [ID6602]

    Awaiting development Reference number: GID-TA11809 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Belzutifan with pembrolizumab and lenvatinib for untreated advanced clear cell renal cell carcinoma [ID6605]

    Awaiting development Reference number: GID-TA11751 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Camlipixant for treating refractory or unexplained chronic cough [TSID12072]

    Awaiting development Reference number: GID-TA11707 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Inclisiran for treating familial hypercholesterolaemia and elevated low density lipoprotein cholesterol in people 12 to 17 years [TSID12129]

    Awaiting development Reference number: GID-TA11698 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Delgocitinib for Chronic Hand Eczema [ID12188]

    Awaiting development Reference number: GID-TA11777 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Tasimelteon for treating sleep disturbance associated with Smith-Magenis syndrome [TSID12191]

    Awaiting development Reference number: GID-TA11746 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Golimumab biosimilar for Rheumatoid Arthritis, Juvenile Arthritis, Ankylosing Spondylitis, Axial Spondyloarthropathy, Psoriatic Arthritis, and Ulcerative Colitis [ID12208]

    Awaiting development Reference number: GID-TA11778 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Atezolizumab for adjuvant treatment of circulating tumour DNA-positive high-risk muscle-invasive bladder cancer after cystectomy [ID6515]

    Awaiting development Reference number: GID-TA11654 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Datopotamab deruxtecan with durvalumab and carboplatin for untreated TROP2-positive advanced non-small-cell lung cancer without actionable genomic alterations [ID6522]

    Awaiting development Reference number: GID-TA11671 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development